September 16, 2021 21:50 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
PM Modi congratulates new ministers in Gujarat govt | Virat Kohli to step down as T20 India captain after T20 World Cup | Union Cabinet approves Rs 30,600 cr for 'Bad Bank' | Sensex hits fresh all time high, Nifty makes fresh peak | AAP promises 300 units free power for every household, waive old dues in poll-bound UP
Serum Institute gets DCGI nod to resume Covid-19 vaccine Covid-19 Vaccine
Image Credit: Pixabay

Serum Institute gets DCGI nod to resume Covid-19 vaccine

India Blooms News Service | @indiablooms | 16 Sep 2020, 10:55 am

New Delhi/IBNS: The Serum Institute of India (SII) has got the nod of the Drug Controller General of India (DCGI) to resume the phase two and three trials for Covid-19 vaccine, media reports said. 

The SII had reportedly sought permission from the DCGI to resume trials for the vaccine developed by pharmaceutical giant AstraZeneca and Oxford University.

The Oxford vaccine trial was first halted by AstraZeneca after a suspected serious adverse reaction was seen in a participant in the United Kingdom last week.

Following the development, the SII had also halted the vaccine trials in the country, but of course after being pulled up by the DCGI. 

The central drug regulator had pulled up the SII for not informing it about the pause of vaccine trials in other nations.

AstraZeneca last Saturday resumed the trials for the vaccine.